S100B Measured in Blood Samples as a Prognostic Biomarker of Functional Capacity and Vital Status in Moderate and Severe Traumatic Brain Injury Patients: Systematic Review and Meta-Analysis

Moderate and severe traumatic brain injury (TBI) can lead to harmful consequences for trauma victims. S100B is a widely studied biomarker to predict the outcomes of this injury, but gaps in knowledge about this protein make its clinical application still uncertain. We investigated the potential prog...

Full description

Saved in:
Bibliographic Details
Main Authors: Lillian Caroline Fernandes, Dyenily Alessi Sloboda, Thamires de Oliveira Rocha, Lilia de Souza Nogueira, Ramon Antonio Oliveira, Augusto Magno Tranquezi Cordeiro, Wellingson Silva Paiva, Rita de Cassia Almeida Vieira, Leda Leme Talib, Regina Marcia Cardoso de Sousa
Format: Article
Language:English
Published: Mary Ann Liebert 2024-11-01
Series:Neurotrauma Reports
Subjects:
Online Access:https://www.liebertpub.com/doi/10.1089/neur.2024.0101
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850275197927555072
author Lillian Caroline Fernandes
Dyenily Alessi Sloboda
Thamires de Oliveira Rocha
Lilia de Souza Nogueira
Ramon Antonio Oliveira
Augusto Magno Tranquezi Cordeiro
Wellingson Silva Paiva
Rita de Cassia Almeida Vieira
Leda Leme Talib
Regina Marcia Cardoso de Sousa
author_facet Lillian Caroline Fernandes
Dyenily Alessi Sloboda
Thamires de Oliveira Rocha
Lilia de Souza Nogueira
Ramon Antonio Oliveira
Augusto Magno Tranquezi Cordeiro
Wellingson Silva Paiva
Rita de Cassia Almeida Vieira
Leda Leme Talib
Regina Marcia Cardoso de Sousa
author_sort Lillian Caroline Fernandes
collection DOAJ
description Moderate and severe traumatic brain injury (TBI) can lead to harmful consequences for trauma victims. S100B is a widely studied biomarker to predict the outcomes of this injury, but gaps in knowledge about this protein make its clinical application still uncertain. We investigated the potential prognostic value of S100B for functional capacity and vital status up to 12 months after moderate and severe TBI and compared its performance when samples of this biomarker are collected in the early (≤6 h) and late (>6 h) phases following the injury. The systematic review followed the recommendations of Cochrane Methods Prognosis and Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The protocol was registered with The International Prospective Register of Systematic Reviews (PROSPERO). The searches were carried out in the Embase, Psycinfo, Medline, and Scopus databases. The meta-analysis was carried out in R® version 4.2.3. Thirty-seven studies were included. The majority indicated higher concentrations of S100B in patients with unfavorable outcomes. In the meta-analysis, S100B showed good discriminative capacity for functional capacity at 3 and 6 months (pooled area under the curve [AUC]: 0.803 and 0.841), but unsatisfactory at 12 months (pooled AUC: 0.592) and for vital status, the pooled AUC was 0.818 for hospital discharge and 6 months, with worse results for 3 and 12 months (AUC: 0.687 and 0.731, respectively). Late samples showed better prognostic performance for functional capacity and vital status. The review indicated that S100B is a promising tool for estimating prognosis up to 6 months after moderate and severe TBI, especially when late samples are analyzed.
format Article
id doaj-art-9b7bcd8d59cf4b068f11a7afe64108a6
institution OA Journals
issn 2689-288X
language English
publishDate 2024-11-01
publisher Mary Ann Liebert
record_format Article
series Neurotrauma Reports
spelling doaj-art-9b7bcd8d59cf4b068f11a7afe64108a62025-08-20T01:50:52ZengMary Ann LiebertNeurotrauma Reports2689-288X2024-11-01511113115010.1089/neur.2024.0101S100B Measured in Blood Samples as a Prognostic Biomarker of Functional Capacity and Vital Status in Moderate and Severe Traumatic Brain Injury Patients: Systematic Review and Meta-AnalysisLillian Caroline Fernandes0Dyenily Alessi Sloboda1Thamires de Oliveira Rocha2Lilia de Souza Nogueira3Ramon Antonio Oliveira4Augusto Magno Tranquezi Cordeiro5Wellingson Silva Paiva6Rita de Cassia Almeida Vieira7Leda Leme Talib8Regina Marcia Cardoso de Sousa9Departamento de Enfermagem Médico-Cirúrgica, Escola de Enfermagem da, Universidade de São Paulo, São Paulo, Brasil.Departamento de Enfermagem, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brasil.Programa Pós-Graduação de Enfermagem na Saúde do Adulto, Escola de Enfermagem da Universidade de São Paulo, Universidade de São Paulo, São Paulo, Brasil.Departamento de Enfermagem Médico-Cirúrgica, Escola de Enfermagem da, Universidade de São Paulo, São Paulo, Brasil.Departamento de Enfermagem Médico-Cirúrgica, Escola de Enfermagem da, Universidade de São Paulo, São Paulo, Brasil.Laboratório de Investigação Médica 27 (LIM-27), Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Universidade de São Paulo, São Paulo, Brasil.Divisão de Neurocirurgia, Hospital das Clínicas da Faculdade de Medicina da, Universidade de São Paulo, Universidade de São Paulo, São Paulo, Brasil.Departamento de Enfermagem do Campus de Lagarto, Universidade Federal de Sergipe, Lagarto, Brasil.Laboratório de Investigação Médica 27 (LIM-27), Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Universidade de São Paulo, São Paulo, Brasil.Departamento de Enfermagem Médico-Cirúrgica, Escola de Enfermagem da, Universidade de São Paulo, São Paulo, Brasil.Moderate and severe traumatic brain injury (TBI) can lead to harmful consequences for trauma victims. S100B is a widely studied biomarker to predict the outcomes of this injury, but gaps in knowledge about this protein make its clinical application still uncertain. We investigated the potential prognostic value of S100B for functional capacity and vital status up to 12 months after moderate and severe TBI and compared its performance when samples of this biomarker are collected in the early (≤6 h) and late (>6 h) phases following the injury. The systematic review followed the recommendations of Cochrane Methods Prognosis and Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The protocol was registered with The International Prospective Register of Systematic Reviews (PROSPERO). The searches were carried out in the Embase, Psycinfo, Medline, and Scopus databases. The meta-analysis was carried out in R® version 4.2.3. Thirty-seven studies were included. The majority indicated higher concentrations of S100B in patients with unfavorable outcomes. In the meta-analysis, S100B showed good discriminative capacity for functional capacity at 3 and 6 months (pooled area under the curve [AUC]: 0.803 and 0.841), but unsatisfactory at 12 months (pooled AUC: 0.592) and for vital status, the pooled AUC was 0.818 for hospital discharge and 6 months, with worse results for 3 and 12 months (AUC: 0.687 and 0.731, respectively). Late samples showed better prognostic performance for functional capacity and vital status. The review indicated that S100B is a promising tool for estimating prognosis up to 6 months after moderate and severe TBI, especially when late samples are analyzed.https://www.liebertpub.com/doi/10.1089/neur.2024.0101biomarkersprognosisS100B proteinsystematic reviewtraumatic brain injury
spellingShingle Lillian Caroline Fernandes
Dyenily Alessi Sloboda
Thamires de Oliveira Rocha
Lilia de Souza Nogueira
Ramon Antonio Oliveira
Augusto Magno Tranquezi Cordeiro
Wellingson Silva Paiva
Rita de Cassia Almeida Vieira
Leda Leme Talib
Regina Marcia Cardoso de Sousa
S100B Measured in Blood Samples as a Prognostic Biomarker of Functional Capacity and Vital Status in Moderate and Severe Traumatic Brain Injury Patients: Systematic Review and Meta-Analysis
Neurotrauma Reports
biomarkers
prognosis
S100B protein
systematic review
traumatic brain injury
title S100B Measured in Blood Samples as a Prognostic Biomarker of Functional Capacity and Vital Status in Moderate and Severe Traumatic Brain Injury Patients: Systematic Review and Meta-Analysis
title_full S100B Measured in Blood Samples as a Prognostic Biomarker of Functional Capacity and Vital Status in Moderate and Severe Traumatic Brain Injury Patients: Systematic Review and Meta-Analysis
title_fullStr S100B Measured in Blood Samples as a Prognostic Biomarker of Functional Capacity and Vital Status in Moderate and Severe Traumatic Brain Injury Patients: Systematic Review and Meta-Analysis
title_full_unstemmed S100B Measured in Blood Samples as a Prognostic Biomarker of Functional Capacity and Vital Status in Moderate and Severe Traumatic Brain Injury Patients: Systematic Review and Meta-Analysis
title_short S100B Measured in Blood Samples as a Prognostic Biomarker of Functional Capacity and Vital Status in Moderate and Severe Traumatic Brain Injury Patients: Systematic Review and Meta-Analysis
title_sort s100b measured in blood samples as a prognostic biomarker of functional capacity and vital status in moderate and severe traumatic brain injury patients systematic review and meta analysis
topic biomarkers
prognosis
S100B protein
systematic review
traumatic brain injury
url https://www.liebertpub.com/doi/10.1089/neur.2024.0101
work_keys_str_mv AT lilliancarolinefernandes s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT dyenilyalessisloboda s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT thamiresdeoliveirarocha s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT liliadesouzanogueira s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT ramonantoniooliveira s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT augustomagnotranquezicordeiro s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT wellingsonsilvapaiva s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT ritadecassiaalmeidavieira s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT ledalemetalib s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis
AT reginamarciacardosodesousa s100bmeasuredinbloodsamplesasaprognosticbiomarkeroffunctionalcapacityandvitalstatusinmoderateandseveretraumaticbraininjurypatientssystematicreviewandmetaanalysis